PHARMACOKINETICS OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 ADMINISTRATION IN CANCER-PATIENTS

被引：0
作者：
CARUSO, B
GIAVARINA, D
JIRILLO, A
GIAVARINA, M
BALLI, M
机构：
[1] LEGNAGO HOSP,CLIN CHEM LAB,VERONA,ITALY
[2] LEGNAGO HOSP,DEPT RADIOTHERAPY & ONCOL,VERONA,ITALY
来源：
EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA | 1992年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Data from a clinical trial with recombinant Interleukin (rIL-2) subcutaneousy administered are here reported. Five patients with cancer were administered with r-IL2. Serum levels were measured on serial samples by immunoenzymatic method. This method is easier than biological methods, allowing to measure rIL-2 only as antigen. Therefore, immunoenzymatic method can be on support in the comprehensive study of IL-2 farmacokynetic. rIL-2 was detectable in serum in all the patient treated, with different levels and time.
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [31] SERUM INTERLEUKIN-2 LEVELS IN RELATION TO THE NEUROENDOCRINE STATUS IN CANCER-PATIENTS
    LISSONI, P
    TANCINI, G
    ROVELLI, F
    CATTANEO, G
    ARCHILI, C
    BARNI, S
    BRITISH JOURNAL OF CANCER, 1990, 62 (05) : 838 - 839
  • [32] Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2
    DiFelice, G
    Fumagalli, L
    Majorca, F
    Barni, S
    Ardizzoia, A
    Tancini, G
    Lissoni, P
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1996, 10 (04) : 98 - 99
  • [33] SYSTEMIC ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-2 IN MICE
    CHANG, AE
    HYATT, CL
    ROSENBERG, SA
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1984, 3 (05): : 561 - 572
  • [34] EFFECTS OF ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-2 IN DOGS
    CAIN, GR
    KAWAKAMI, T
    TAYLOR, N
    CHAMPLIN, R
    COMPARATIVE HAEMATOLOGY INTERNATIONAL, 1992, 2 (04): : 201 - 207
  • [35] CORRELATION OF SERUM INTERLEUKIN-2 LEVELS, SOLUBLE INTERLEUKIN-2 RECEPTORS AND LYMPHOCYTE-T SUBSETS IN CANCER-PATIENTS
    LISSONI, P
    BARNI, S
    ROVELLI, F
    RESCALDANI, R
    RIZZO, V
    BIONDI, A
    TANCINI, G
    TUMORI, 1990, 76 (01) : 14 - 17
  • [36] Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
    Eton, O
    Rosenblum, MG
    Legha, SS
    Zhang, WH
    East, MJ
    Bedikian, A
    Papadopoulos, N
    Buzaid, A
    Benjamin, RS
    CANCER, 2002, 95 (01) : 127 - 134
  • [37] PHASE-I STUDY COMPARING CONTINUOUS INFUSION OF RECOMBINANT INTERLEUKIN-2 BY SUBCUTANEOUS OR INTRAVENOUS ADMINISTRATION
    LEAHY, MG
    PITFIELD, D
    POPERT, S
    GALLAGHER, CJ
    OLIVER, RTD
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) : 1049 - 1051
  • [38] CHANGES IN SOLUBLE INTERLEUKIN-2 RECEPTOR (SIL-2R) LEVELS IN CANCER-PATIENTS RECEIVING RECOMBINANT INTERLEUKIN-2(RIL-2) AND LYMPHOKINE ACTIVATED KILLERS (LAK)
    MARSHALL, GD
    RUCKER, KT
    PRICE, JO
    COPENHAVER, JD
    WEST, WH
    JOURNAL OF LEUKOCYTE BIOLOGY, 1987, 42 (04) : 362 - 362
  • [39] IN-VITRO ANTITUMOR-ACTIVITY OF EOSINOPHILS FROM CANCER-PATIENTS TREATED WITH SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN-2 - ROLE OF INTERLEUKIN-5 (VOL 54, PG 8, 1993)
    RIVOLTINI, L
    VIGGIANO, V
    SPINAZZE, S
    SANTORO, A
    COLOMBO, MP
    TAKATSU, K
    PARMIANI, G
    INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (05) : 887 - 887
  • [40] EXPANSION OF PERIPHERAL-BLOOD NATURAL-KILLER-CELLS CORRELATES WITH CLINICAL OUTCOME IN CANCER-PATIENTS RECEIVING RECOMBINANT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA(2)
    ATZPODIEN, J
    KIRCHNER, H
    KORFER, A
    HADAM, M
    SCHOMBURG, A
    MENZEL, T
    DECKERT, M
    FRANZKE, A
    VOLKENANDT, M
    DALLMANN, I
    GROSSE, J
    POLIWODA, H
    TUMOR BIOLOGY, 1993, 14 (06) : 354 - 359
12345